Clinical Trial

This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.

Study acronym: NouvNeu001-01
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a phase 1/2 clinical study to evaluate the safety, tolerability, feasibility, and preliminary efficacy of NouvNeu001 in patients with advanced Parkinson's Disease.
Protocol Amendment History 1 change
critical Phase changed: Phase 1 -> Phase 1/2 2026-05-12
Trial Details
NCT Number NCT07102342
Lead Sponsor iRegene Therapeutics Co., Ltd.
Conditions Parkinson Disease
Enrollment 5 participants
Start Date 2026-01-12
Primary Completion 2027-09 (estimated)
Study Completion 2032-09 (estimated)
Updated on ClinicalTrials.gov 2026-05-11